Participation in Europe’s largest nuclear medicine congress drives innovation, strategic partnerships, and excellence in radiopharmaceutical production.

Between October 4th and 8th, 2025, Villas Boas Radiofármacos attended the 38th Annual Congress of the European Association of Nuclear Medicine (EANM’25), held at the CCIB in Barcelona.

EANM’25 brought together more than 8,200 participants, including clinicians, researchers, industry leaders, and young professionals. The event featured over 200 scientific sessions organized across thematic tracks such as theranostics, neuroimaging, nuclear cardiology, and radiopharmaceutical production.

The event also hosted an exhibition of more than 180 companies, spanning approximately 5,000 m², showcasing product demonstrations, innovations, and collaboration opportunities.

During the congress, our representatives focused on essential topics for radiopharmaceutical production, such as:

• New therapeutic molecules / synthesis routes

• Quality standards and GMP (Good Manufacturing Practice) certifications

• Logistical challenges and international regulations

• Partnerships for translational research and industrial scaling

Our participation reinforces our mission to invest in innovation, quality, and international cooperation, positioning Villas Boas among the Brazilian companies with recognized standing in the global nuclear medicine landscape.